Answers are grounded in this paper and cite their sources.
We report our series of 12 consecutive patients with bilateral acute iris transillumination (BAIT), including one unilateral case. Over the past 3 years, we diagnosed BAIT in 11 women and one man (mean age 52.3 years), based on characteristic iris transillumination with distorted pupils and lack of stromal atrophy, often preceded by pseudouveitis to a variable extent. A third of these patients were seen at onset of debilitating photophobia. Interestingly, initial examination showed miotic, regular pupils, rare anterior chamber cells and no iris transillumination. Empirical treatment with corticosteroid drops was initiated in these eyes. These eyes evolved to a BAIT phenotype in the following days. Viral serology (Herpes simplex virus (HSV), varicella zoster virus (VZV), cytomegalovirus (CMV) and Epstein-Barr virus (EBV)) performed in six patients with recent onset of BAIT failed to consistently show seropositivity for any of the viruses. An anterior chamber tap was performed in one eye and yielded negative PCR results for HSV, VZV and CMV. All patients had a single episode of extensive diffuse or patchy pigment loss. Ocular hypertension occurred in four patients (33.3%) and was controlled with pressure-lowering drops. Dilated fundoscopy and fundus autofluorescence showed no significant abnormalities. Twenty-two of 23 affected eyes were phakic. The patient with unilateral pseudophakia had marked asymmetric involvement, with less transillumination and pupillary distortion in the pseudophakic eye. Three patients (five eyes) underwent phacoemulsification with two Morcher aniridia 50C rings in the capsular bag (Morcher GMBH, Stuttgart, Germany). Photophobia largely resolved following surgery, and postoperative course was uneventful. We obtained a history of recent oral moxifloxacin intake (average of 2 weeks prior to onset of ocular symptoms) in 11 of 12 patients. In one patient, we were unable to confirm the antibiotic prescribed for her lower airway infection. Patients used recommended doses of moxifloxacin (5–10 days one tablet of 400 mg), except for two patients (14 days). Indications were airway infections (upper or lower) in 10 patients and erysipelas in one patient (male patient). General health was remarkable for asthma in three patients, chronic obstructive pulmonary disease (COPD) and chronic lymphatic leukaemia in one patient. We report on our series of 12 BAIT patients, including five eyes with successful cataract surgery with Morcher aniridia 50c rings to resolve photophobia (Fig. 1). The aetiology of BAIT remains to be elucidated. Reported cases are commonly associated with viral respiratory disease and/or oral moxifloxacin intake. In the largest series, to date, consisting of 26 BAIT patients, no consistent association with either could be provided (Tugal-Tutkun et al. 2011). Respiratory infections are the commonest indication for moxifloxacin use, which renders it difficult to differentiate between the effect of the underlying infection and moxifloxacin. In our series, the vast majority (91.7%) had a history of oral moxifloxacin intake. A few cases of BAIT have been reported in non-respiratory infections, such as our case of erysipelas (Willermain et al. 2010). Moxifloxacin has some unique characteristics that make the association with BAIT striking. It shows specific interaction with melanin, causing accumulation in melanin-rich tissues such as the iris and ciliary body (Robertson et al. 2005). Oral moxifloxacin use results in significantly higher intraocular fluid levels compared to other fluoroquinolones in healthy humans in samples obtained during routine surgery (Hariprasad et al. 2006). Levels in highly melanin-rich tissue such as the iris pigment epithelium are anticipated to be markedly higher than in the aqueous. Epidemiologic studies have also found an association between moxifloxacin and uveitis, in contrast with other fluoroquinolones (Sandhu et al. 2016). Interestingly, moxifloxacin use is by far the highest in Belgium compared to all other European countries (data from the European Centre for Disease Prevention and Control, available on ecdc.europa.eu).
No takes yet. Share an insight, caveat, or question.
Kreps et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: